# Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV

> **NCT00348387** · PHASE3 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 600 (actual)

## Conditions studied

- Poliomyelitis
- Polio

## Interventions

- **BIOLOGICAL:** Poliomyelitis Vaccine inactivated
- **BIOLOGICAL:** Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)

## Key facts

- **NCT ID:** NCT00348387
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2008-09
- **Final completion:** 2008-12
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2014-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00348387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00348387, "Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00348387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*